Bioethics News

Turmoil at Troubled Fertility Company Ovascience

January 3, 2017

(MIT Technology Review) – Ovascience’s lead product, called Augment, involves harvesting energy-making structures called mitochondria from the precursor cells. These are then injected along with sperm into the eggs of a woman undergoing IVF treatment with an eye toward improving the chance of a pregnancy. With limited data supporting its ability to improve IVF success rates, Augment was never offered in the U.S., but has been available in 10 clinics in Japan, Canada, and the United Arab Emirates.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.